Login to Your Account

Pharma: Clinic Roundup

Monday, April 2, 2012
• Shire plc, of Dublin, Ireland, said that once-daily SPD476 (MMX mesalamine) did not reduce the rate of recurrence of diverticulitis over a 2-year treatment period in a Phase III (PREVENT2) trial. It also failed to separate from placebo on its secondary endpoint. A second trial (PREVENT1) still has results pending, but the company does not intend to pursue a regulatory filing for MMX mesalamine in that indication.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription